Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy

Documenti analoghi

• Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry ( IKF ‐ PARAGON study)
  di: Thorsten O. Goetze, et al.
  Pubblicazione: (2025)
• Patterns of recurrence after curative resection and adjuvant chemotherapy in gastric and gastroesophageal junction cancer
  di: Chengzhi Wei, et al.
  Pubblicazione: (2026)
• Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second‐line setting
  di: Ángel Serna, et al.
  Pubblicazione: (2026)
• Correction to: Simulations to predict clinical trial outcome of bevacizumab plus chemotherapy vs. chemotherapy alone in patients with first‐line gastric cancer and elevated plasma VEGF‐A
  Pubblicazione: (2024)
• Immune checkpoint inhibitors plus chemotherapy in first‐line endometrial cancer treatment: Still the era of microsatellites?
  di: Mauro Francesco Pio Maiorano, et al.
  Pubblicazione: (2024)